Hemab Therapeutics Inc. Common Stock

COAG | NASDAQ

Price Alert Chart Builder DCF Calculator

$41.38

+$0.96 (+2.38%)

At close: Oct 30, 2026, 3:59 PM ET

$41.66

+$0.28 (+0.68%)

After-hours: Oct 30, 2026, 7:48 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $1.93B

Enterprise Value $1.48B

Beta 1.85

Average Volume 438.66K

Shares Outstanding (Diluted) 30.11M

Shares Change YoY N/A

Institutional Ownership N/A

Exchange NASDAQ

ISIN US4234941031

Price Performance

Price Change 1M 34.2%

Price Change 3M -13.0%

Price Change 6M 21.7%

Price Change YTD N/A

Price Change 1Y N/A

Price Change 3Y N/A

Price Change 5Y N/A

1M CAGR (ann.) 0.6%

1Y CAGR (ann.) N/A

5Y CAGR (ann.) N/A

All-Time CAGR 48.8%

Valuation

PE Ratio -31.59

Forward PE N/A

PEG Ratio -0.32

Forward PEG 0.33

PS Ratio N/A

Forward PS N/A

PB Ratio 4.26

P/FCF Ratio -43.71

P/Adj. FCF Ratio -42.45

P/OCF Ratio -28.15

EV/Sales N/A

EV/EBIT -29.71

EV/EBITDA -29.80

EV/FCF -33.39

Earnings Yield -3.2%

FCF Yield -2.3%

Adj. FCF Yield -2.4%

Financial Health

Net Cash $457.46M

Total Debt $1.03M

Cash & Short-Term Investments $457.46M

Total Assets $467.78M

Current Ratio 35.85

Quick Ratio 35.85

Debt / Equity Ratio 0.00

Debt / EBITDA -0.02

Debt / FCF -0.02

OCF / Debt -43.10

Interest Coverage 0.00

Altman Z-Score 86.80

Piotroski F-Score 1

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -3.0%

Returns

Return on Assets -10.0%

Return on Equity -36.6%

Return on Invested Capital -10.9%

Return on Capital Employed -10.9%

Return on Tangible Assets -10.0%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 3

EPS Growth Next 3Y -45.3%

Revenue Growth Next 3Y N/A

Earnings Date Nov 10, 2026

EPS Estimate (next Q) -$0.51

EPS Growth Est (next Q) N/A

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $51.40

Price Target Upside 24.2%

Cash Flow

Operating Cash Flow $-44.22M

Free Cash Flow $-44.22M

Adj. Free Cash Flow $-45.54M

FCF Per Share -$1.47

OCF Per Share -$1.47

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-75K

Operating Income $-49.69M

EBITDA $-49.55M

Net Income $-46.84M

EPS (Diluted) -$1.31

Revenue / Employee N/A

Profit / Employee $-793.85K

Employees 59